CSTL
Castle Biosciences, Inc. · Healthcare · Medical - Diagnostics & Research
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones -14.6% · nuevas posiciones netas 0.0% — fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q1 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 76 | -1 | 16.76M | $400.39M | +6 | −6 |
| Q1 2026 | 79 | -9 | 16.13M | $395.93M | +4 | −13 |
| Q4 2025 | 87 | +2 | 17.12M | $665.58M | +2 | — |
| Q3 2025 | 16 | 0 | 9.41M | $214.29M | +1 | −1 |
| Q2 2025 | 13 | -1 | 9.39M | $191.81M | — | −1 |
| Q1 2025 | 11 | 0 | 4.13M | $82.76M | +1 | −1 |
| Q4 2024 | 11 | +2 | 4.84M | $128.97M | +4 | −2 |
| Q3 2024 | 8 | 0 | 2.64M | $75.25M | — | — |
| Q2 2024 | 8 | — | 1.95M | $42.47M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 828.53K | +14.7% | $16.59M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | State Street Global Advisors ✦ (pasivo) | 715.03K | +0.7% | $14.31M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Renaissance Technologies ✦ | 701.20K | +2.4% | $14.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Geode Capital Management ✦ (pasivo) | 649.85K | +3.5% | $13.01M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Geode Capital Management ✦ (pasivo) | 649.85K | +3.5% | $13.01M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 258.38K | -69.0% | $5.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 258.38K | -69.0% | $5.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Millennium Management ✦ | 254.75K | -53.6% | $5.10M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 236.22K | -56.8% | $4.73M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 189.18K | +108.9% | $3.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 189.18K | +108.9% | $3.79M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 139.78K | Nuevo | $2.80M | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 137.02K | +548.9% | $2.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | T. Rowe Price ✦ | 23.70K | +4.4% | $475,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Two Sigma Investments | $2.80M | 0.0% |
Posición cerrada
| Arrowstreet Capital | $770,265 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 186 tenedores, 27.52M acciones, $653.08M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 1.73K acc. · $51,191
Officer, Director · 1.10K acc. · $33,022
Officer, Director · 2.71K acc. · $81,474
Officer, Director · 2.31K acc. · $69,226
Officer, Director · 278 acc. · $8,346
Officer · 24.91K acc. · $741,511
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología